
Oncology NEWS International
- Oncology NEWS International Vol 17 No 5
- Volume 17
- Issue 5
First trial of RXR agonist
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.
Articles in this issue
over 17 years ago
Immunotherapy agent promising in NSCLCover 17 years ago
NCCN greenlights nilotinib for imatinib-resistant CML patientsover 17 years ago
No overall survival benefit for dose-intense regimen in SCLCover 17 years ago
Make a note of new smoking cessation codesover 17 years ago
Relistor for treating OICover 17 years ago
Experts argue against need for phase III proton Rx trialsover 17 years ago
Spotlight on Cancer Centersover 17 years ago
Novel peptide vaccine promising in myeloid leukemiaover 17 years ago
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































